Dossier overview
4
research areas
3
references
3
handling notes
01
Mechanism of action
VIP binds the G-protein coupled VPAC1 and VPAC2 (also PAC1 with lower affinity), activating adenylate cyclase and cAMP signalling. Physiological roles include smooth-muscle relaxation, immunomodulation, and circadian regulation.
02
Research applications
- physiology
- VIPoma diagnosis and management research
- Pulmonary and airway research (incl. VIP )
- Cancer-targeting research (VIP / PACAP as imaging and therapeutic targets)
Evidence at a glance
What's behind this profile
3 citations · 2016–2019
- Review
- 3
Narrative or systematic reviews; no primary data.
Publication years
- 16
- 17
- 18
- 19
Counts are derived from the cited studies below. A study covering both in vivo and in vitro work is counted by its primary model. Sample size is reported in 0 of 3 citations. Findings remain model-specific and are not extrapolated to therapeutic use.
03
Study references
Each profile cites a minimum of two peer-reviewed sources, with model type and reported sample size where the source provides it. Findings are model-specific and must not be extrapolated to therapeutic use.
Vasoactive intestinal peptide / pituitary adenylate cyclase activating polypeptide, and their receptors and cancer
2016
Moody TW et al. · Current Opinion in Endocrinology, Diabetes and Obesity
- Model
- Narrative review of VIP / PACAP receptor biology and cancer applications
- Sample
- N/A (review)
Reviewed VPAC1, VPAC2, and PAC1 overexpression in common cancers and the development of VIP-based tumour imaging and targeted-therapy candidates.
Vasoactive Intestinal Peptide-Secreting Tumors: A Review
2019
Siddappa PK et al. · Pancreas
- Model
- Narrative review of VIPoma diagnosis and management
- Sample
- N/A (review)
Reviewed VIPomas as rare neuroendocrine tumours causing watery-diarrhoea syndromes and the multimodal approaches used for symptom and tumour control.
Role of vasoactive intestinal peptide in osteoarthritis
2016
Jiang W et al. · Journal of Biomedical Science
- Model
- Narrative review of VIP in osteoarthritis pathophysiology
- Sample
- N/A (review)
Reviewed evidence that VIP down-regulation is associated with increased pro-inflammatory cytokines in osteoarthritic joints, framing VIP and as exploratory therapeutic candidates.
Evidence caveats
- VIP has extensive published basic-science literature (>1,500 PubMed records on review/clinical-trial filter alone); the three citations here are clinical-context anchors rather than a comprehensive review.
- Synthetic VIP is not FDA-approved for any indication. Clinical use is investigational.
04
Storage and handling
Store under controlled laboratory conditions with batch and preparation details recorded.
- Synthetic VIP is hygroscopic; store under controlled humidity per supplier guidance.
- Maintain batch and supplier documentation for research reagent use.
- Research-only inventory; not for human use.